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T he heart beats ≈2.5 to 4 billion times in an average human life; however, despite hydrolyzing 20× its mass in ATP each day, it only stores enough energy for several heartbeats. 1 As such, the heart must continuously adapt to changing nutritional supply and physiological demands to meet ongoing energy needs. Indeed, the heart can generate ATP from diverse sources such as carbohydrates, lipids, lactate, amino acids, and ketone bodies. Given the critical need for a constant supply of energy, it is not surprising that most cardiovascular diseases involve disturbances in cardiac metabolism. 2 Moreover, disturbances in metabolism that occur in diseases such as diabetes mellitus directly impact cardiac metabolism. It is also becoming more apparent that heart disease per se can affect systemic metabolism. 3 Thus, disturbances in systemic and cardiac metabolism may initiate a vicious cycle that causes and perpetuates cardiovascular diseases. The American Heart Association has recognized the growing importance of biomedical research in closing the conceptual gap between cardiac metabolism and cardiovascular health and has recently released a scientific statement on emerging aspects of cardiac metabolism. 4 Traditional metabolic research has usually relied on a reductionist approach, where the role of specific metabolic pathways in cardiovascular diseases are investigated in a narrowly focused fashion. The postgenomic era has led to the development of omics tools (referring to genomics, transcriptomics, proteomics, and metabolomics) for discovery-based science that provide a more unbiased and comprehensive view of the molecular changes that occur in different disease states.
In general, omics studies seek to define networks in which genetic variation (genomics) leads to changes in gene expression (transcriptomics) to affect protein expression and posttranslational modification (proteomics and posttranslational modification-omics; Figure 1A ). More recently, metabolomics has emerged as a means for measuring chemical intermediates, or metabolites, in a variety of biological samples, including plasma, urine, saliva, and tissues. The number of metabolites was once thought to be relatively small compared with other molecular variables, but as metabolomics technologies have advanced, the breadth of measurable metabolites has been expanding exponentially. 5 Although genetic variation in populations exists at birth, metabolomics profiling provides a means for integrating genomic, epigenetic, transcriptomic, and proteomic variation, while also being responsive to environmental factors such as dietary intake, gut microbiota variation, physical activity, and environmental exposures ( Figure 1B) . Thus, the study of the metabolome can provide important insight into cardiovascular disease pathogenesis as well as offering the potential to identify new cardiovascular disease biomarkers.
The field of metabolomics and its applications to cardiovascular diseases continue to evolve rapidly. In this review, we will discuss the current state of metabolomics technologies, including consideration of various metabolomics platforms and elements of study design; the emerging utility of stable isotopes for metabolic flux studies; and, finally, the use of metabolomics to better understand mechanisms underlying specific cardiovascular diseases.
Nontargeted and Targeted Metabolomics
Several metabolomics approaches exist for interrogating a biological question of interest. Nontargeted metabolomics is a comprehensive analytic approach that attempts to detect, identify, and relatively quantify as many metabolites in a biological sample as possible. In doing so, nontargeted approaches aim to discriminate unique metabolite features associated with a genotype, pharmacological treatment, clinical subpopulation, or other comparative grouping, usually by comparison to appropriate control groups. For the sake of this article, we will not refer to this approach as targeted metabolomics (see below). Major challenges of nontargeted metabolomics include metabolite identification, which requires established or in-house metabolite databases, lack of reliable fragmentation chemistries for all biomolecules of interest, and chemical/biochemical modification of metabolites resulting in spectral shifts (see the following reviews for more detail [6] [7] [8] ). Nevertheless, the wide coverage provided by nontargeted approaches has the potential to identify novel metabolic pathways, disease biomarkers, and drug-derived metabolites.
In contrast, in targeted metabolomics, a selective group of metabolites-often clusters of chemically related analytes-are measured with tailored analytic approaches for absolute quantification. A major benefit of targeted techniques is increased sensitivity and selectivity, because metabolite extraction, compound separation (if desired), and instrumentation parameters can be optimized to develop quantitative metabolite panels. Quantification is typically achieved by inclusion of stable isotope-labeled internal standards or through the development of calibration curves with an external standard. This is in contrast to nontargeted metabolomics, where metabolites are presented by methods of relative quantification, typically involving peak area comparison of the analyte(s) of interest.
Metabolomics Study Considerations and Design
Figure 2 highlights the general phases involved in any metabolomics study. These components are discussed in detail in the following sections.
Experimental Design and Sample Preparation

Anesthesia and Euthanasia
One important consideration when designing animal studies is the method of anesthesia and euthanasia used. Several studies have shown wide-ranging changes in tissue metabolite concentrations depending on whether animals are anesthetized or euthanized before tissue harvest. 9, 10 In general, euthanasia, whether through cervical dislocation, carbon dioxide or isoflurane overdose, leads to metabolite changes consistent with tissue ischemia such as an accumulation of lactate, succinate, and acylcarnitine species. Moreover, there is some variability in metabolic changes depending on the type of anesthesia used, which may not be related to the anesthetic per se but rather how rapidly tissues can be harvested after anesthesia induction. 10 Therefore, whenever possible, tissues should be collected under anesthesia rather than posteuthanasia, and the type of anesthesia 
Data Acquisition and Feature Detection
Analytic Considerations
To apply nontargeted metabolomics to human disease cohorts, which can involve hundreds to thousands of samples, careful design of workflow is required to maintain reproducibility within and between analytic batches. Several good practices for large-scale studies include (1) a method blank for analysis; (2) a pooled sample of the study specimens; and (3) a linearity assessment of biological samples. 12 A method blank sample is treated identically to the biological specimens; however, it has no biological material present. The method blank provides an assessment of potential contaminants that appear as a result of sample handling, processing, and storage. This allows Figure 2 . General metabolomics workflow, which can be viewed as 4 distinct phases. On the generation of a biological question of interest, an experiment is designed, performed, and specimens are collected/prepared for metabolomics assays. Second, samples are profiled by nuclear magnetic resonance (NMR) or mass spectrometry (MS) and metabolite features are detected. Third, statistical analyses are performed to determine significant metabolite features, which can then be identified through database searching and quantified with targeted analyses. Last, metabolite data can be further interrogated with pathway/cluster analyses before the data are interpreted in light of the original hypothesis. In certain circumstances, the metabolomics analyses can result in mechanism/model formulation, which can be probed with stable isotope and flux analysis techniques. Broadly, metabolomics studies are hypothesis generating and can begin another cycle of studies. GC indicates gas chromatography; KO, knockout; LC, liquid chromatography; PC1, principal component 1; PC2, principal component 2; PCA, principal components analysis; and WT, wild-type.
removal of contaminant features from downstream analysis. Pooled metabolite samples are commonly used in nontargeted metabolomics and are prepared by mixing a small, but an equal amount of sample from a fraction of the studies samples, for example, for a study of 1000 samples, a pooled subset of 100 samples is sufficient. The pooled metabolite sample should be included multiple times within an individual batch and also across analytic batches. As the origin of the sample is the same for all analytic batches, the pooled sample approach serves several quality control (QC) purposes. First, the pooled sample aids in the identification of baseline drift and retention time shift of metabolites. Second, the pooled sample allows estimation of technical precision, which is a common quality assurance metric. Last, the pooled sample allows for signal intensity correction because of inter-and intrabatch instrument variability. If possible, depending on sample availability, it is also beneficial to perform dilution studies on a small subset of samples in the study, as this allows linearity assessment of features in the nontargeted panel. As metabolites exist in a large dynamic range of concentration, certain features may saturate the detector, preventing accurate peak area determination. Dilution studies allow for optimization of sample preparation to maximize the number of features that are detectable and quantifiable.
Sample Profiling With Metabolomics Technologies
The diverse chemical nature and wide concentration range of metabolites dictate that no single technique or platform is able to detect and quantify the entire metabolome. Over the past 10 years, the number of metabolite entries in the Human Metabolome Database (HMDB, hmdb.ca) database has expanded from 2200 to >110 000 metabolites, 5, 13, 14 with a recent in silico effort projecting that the metabolome, including drug-derived xenobiotics, could possibly consist of hundreds of thousands of analytes. 15 Thus, the number of metabolites that are currently measured represents only a fraction of the estimated number of metabolites that comprise the entirety of the metabolome. Of the currently detected and quantified metabolites, the majority (≈92 000) are considered physiological/ endogenous; however, a large number are derived from environmental exposures such as food (≈30 000; some overlap with endogenous metabolites), drugs (≈2500), and microbes (≈200). 5, 13, 14 In addition, although blood contains most of the known metabolites (≈18 600), metabolites have been measured in 16 different biofluids, including urine (≈2300), saliva (≈1200), and cerebrospinal fluid (≈450). 5, 13, 14 The 2 most popular platforms for metabolomics analyses are nuclear magnetic resonance (NMR) and mass spectrometry (MS). Both techniques can detect, identify, and quantify metabolites in a high-throughput, automated manner. In this review, we will briefly discuss NMR and MS techniques. A general overview of advantages and disadvantages of the different techniques can be found in Table 1 . More in-depth technical reviews of metabolomics platforms and procedures are available elsewhere. 4, 16, 17 
NMR-Based Metabolomics
Certain atomic nuclei, such as 1 H, 13 C, 15 N, and 31 P, have inherent nuclear spin and hence a magnetic field associated with them. NMR manipulates these magnetic properties by an exciting nuclear spin through rapid changes in an external magnetic field and then recording electromagnetic radiation released as a result of nuclei relaxation. The resonance frequency of the energy released, referred to as the chemical shift, depends on the strength of the magnetic field and the properties of the compound. NMR spectra can display signal splitting because of spin coupling, as the microenvironment of adjacent nuclei affects the resonance frequency of a given nucleus.
One advantage of NMR compared with MS is that the technique is noninvasive and nondestructive, which allows performance of NMR studies in vivo in humans and animals and in situ in perfused tissue systems. In addition, the biological sample is physically isolated from the NMR instrument, resulting in better performance over the continuous operation, whereas in MS, the instrument performance will degrade over time and high ionic strength biofluids will result in significant ion suppression of signal intensity. Furthermore, NMR has diverse spectral libraries and can provide detailed structural information for identification, especially when multidimensional NMR is implemented. Finally, NMR analysis is performed on samples without the need for chemical derivatization, thereby reducing analytic variability. H-NMR has been applied to a variety of applications related to cardiovascular metabolism including in vivo monitoring of myocardial lipids, 18 measurement of total creatine, 19 and targeted protocols for lipoprotein subfractionation from plasma. 20, 21 In comparison to protons, 13 C-nuclei have a wider chemical shift range; however, this comes with a cost of lower sensitivity as the natural abundance of 13 C is only ≈1.1% in nature. On the other hand, the low natural abundance of 13 C is beneficial for leveraging 13 C-NMR with stable 13 C-isotope experiments (discussed in more detail later). For a given metabolite, each 13 C-atom will have a unique resonance shift depending on the chemical microenvironment. In addition, peak splitting of the resonance can occur when a 13 C-atom is covalently adjacent to one or more 13 C-atoms. Thus, 13 C-NMR provides detailed positional information of stable isotope incorporation, which is of great value in isotope tracing studies. This approach has been applied to study substrate uptake in the heart, 22,23 monitor changes in substrate utilization and anaplerosis in pathophysiological states 24, 25 and investigate dynamics of intracardiac tissue triacylglyceride pools. 26, 27 Compared with MS-based techniques, the sensitivity of NMR is very poor (μmol/L versus pmol/L), and the metabolome coverage is quite low (hundreds of metabolites versus thousands). Also, the capital and operating cost of NMR equipment is an order of magnitude higher than gas chromatography (GC)-MS and similar to or greater than top-ofthe-line liquid chromatography (LC)-MS/MS systems. Last, sample size requirements are of concern for NMR. Where MS can be applied to μL quantities of plasma or a few milligrams of tissue, NMR typically requires much larger samples. This is of particular concern in rodent studies, where tissue and plasma yield is small. Recent advances in hyperpolarized NMR remedy some of these limitations because of greatly increased sensitivity and the ability to perform real-time spatial visualization 28, 29 and monitoring of specific enzymatic reactions in in vivo systems. 30, 31 MS-Based Metabolomics MS relies on the ionization of analytes followed by measurement of the intensity of the ions produced, which is recorded according to mass-to-charge ratios (m/z). The spectra of m/z ratios and fragmentation information are helpful in metabolite identification. Mass spectrometers consist of 3 major components (1) the ionization source; (2) the mass analyzer(s); and (3) the ion detector. For more details about ionization types and the different mass analyzers used for metabolomics, please see Tables 2 and 3 , respectively. Mass spectrometers are typically preceded by front-end separation, commonly GC or LC. Chromatographic separation increases selectivity and decreases potential ion suppression effects in the mass spectrometer by reducing the number of coeluting compounds that reach the mass spectrometer at a given time. Chromatography can also aid in separating isobaric species. We will briefly discuss GC-MS and LC-MS technologies for use in metabolomics studies.
Gas Chromatography-Mass Spectrometry GC-MS provides robust analyte separation, reproducible retention times, and peak widths of seconds. GC requires volatile metabolites and gas-phase chemistry; however, most biological metabolites are not volatile by their nature and must be chemically derivatized, which requires dried metabolite extracts, treatment of samples at high temperature and exposure of metabolites to harsh solution conditions. As a result, GC-MS is not the method of choice for chemically-labile, thermally unstable, and easily degradable metabolites (eg, acylcarnitines, acyl-CoAs, intact lipid species, phosphorylated intermediates, α-keto-acids). Despite this drawback, GC-MS is used routinely for profiling of organic/amino acids in tissues and bodily fluids [32] [33] [34] as well as breakdown products of therapeutic and drugs of abuse. 35, 36 GC-MS-based metabolomics has also been used for nonesterified and esterified fatty acid analyses in plasma samples, 37, 38 although GC-MS is not the preferred approach for wide-scale lipidomics.
Among GC platforms, the single quadrupole GC-MS is currently the instrument package most often applied to both targeted and nontargeted metabolomics. Nontargeted applications rely on an established in-house retention time/spectral library because the accurate mass determination is not possible. 33, 39, 40 For GC-MS with electron impact ionization, identification of unknown metabolites is aided by standardized electron energy (ie, 70 eV) for spectral reporting. The standardized electron energy allows easy method transfer between instruments and laboratories, which has resulted in the establishment of large repositories of electron impact-spectra for unknown metabolite identification, for example, the NIST (National Institute of Standards and Technology) database. 41 Advancements in GC-Q-TOF (GC-quad time-of-flight) and GC-Q-Orbitrap technologies have made high-resolution nontargeted metabolomics studies a possibility for GC-MS systems. Coupling the separation capability of GC with accurate mass determination and MS/MS spectral data can enhance discovery-based metabolomics. However, the general pitfalls of GC-MS techniques, including lack of suitability for labile compounds and limited metabolite coverage are still relevant to the more advanced systems.
Liquid Chromatography-Mass Spectrometry
Because of improvements in high-performance LC and ultrahigh performance LC technology and a variety of column GC-MS indicates gas chromatography-mass spectrometry; and LC-MS/MS, liquid chromatography-mass spectrometry/mass spectrometry. chemistries, LC is now able to separate a wide range of metabolites, making it very suitable for high-throughput, comprehensive metabolomic analyses of bodily fluids and tissue samples. The commonly used stationary phase chemistries include reverse phase, hydrophilic interaction chromatography, and porous graphitized carbon. Reverse phase and hydrophilic interaction chromatography are orthogonal chromatographic approaches. Reverse phase chromatography is best applied for nonpolar metabolites analysis, such as glycerolipids, phospholipids, fatty acids, acylcarnitines, and medium/long chain acyl-CoAs. Hydrophilic interaction chromatography approaches are more suitable for polar metabolites, including sugar monomers, nucleotides/nucleosides, phosphate compounds, and organic acids. The hydrophilic interaction chromatography technique provides limited separation for very polar molecules, and hence porous graphitized carbon has been applied for separation of such compounds, for example, glycans, oligosaccharides, and sugar phosphates. 42, 43 As the field continues to advance, 2D chromatography approaches may provide a means to interrogate metabolites of wide-ranging polarity in a single method. 44, 45 Despite the versatile column chemistries available, an ongoing challenge for LC approaches is their less reproducible chromatography compared with GC methods. Continued improvement of column stationary phases and the flexibility of mobile phase and ion pairing reagent selection will likely narrow this gap in the future.
Unlike GC-MS, LC-MS methods do not require volatile analytes and often require very little sample preparation postextraction. Another benefit of LC-MS techniques is minimal in-source fragmentation compared with electron impactbased GC/MS. Thus, the metabolite's chemical backbone is preserved, which aids in the molecular weight and atomic composition determination of an unknown metabolite. Further fragmentation for MS/MS spectral determination can be performed, if desired. In addition, multiple polarity modes for the LC-MS ion source provides coverage of both positively and negatively charged metabolites.
For targeted analyses, LC-MS instruments are typically triple quadrupole because of the high sensitivity and selectivity of monitoring specific ion transitions. For nontargeted and spectral library-assisted applications, TOF and Orbitrap platforms are prevalent because of the instruments' highresolution, accurate mass determination, and the rich spectral data set that can be collected across a wide m/z range, for example, the cardiac lipidome. 46 Nontargeted TOF and Orbitrap approaches rely on spectral library tools for unknown metabolite identification, but this is not necessarily a straightforward proposition as identification can be confounded by isomeric species and metabolite adduct formation.
Direct Injection or Flow-Injection MS Platform
Direct injection or flow-injection MS without LC separation is also an option for metabolomics studies. Importantly, direct or flow-injection MS/MS has high throughput because of short run times (ie, <5 minutes). Furthermore, state-of-the-art tandem and hybrid mass spectrometers have the capacity to analyze complex biological matrices. Direct and flow-injection MS platforms are ideally suited for targeted analyses of clusters of chemically related metabolites (eg, acylcarnitines, amino acids), where extraction methods can be optimized to selectively isolate the metabolites of interest, hence reducing the complexity of the biological matrix. 47 
Statistical Analyses and Feature Identification Metabolomics Data Processing and Analyses
As with other omics technologies, metabolomics studies can generate hundreds (in the case of targeted platforms) to thousands (in the case of nontargeted platforms) of data points per analyzed sample. Thus, the ability to interpret and analyze metabolomics data relies heavily on advanced computational approaches. Considerations and challenges in metabolomics data processing and analyses have recently been reviewed, 48 and several will be discussed in detail here.
Beyond sample preparation and data generation, appropriate processing of metabolomics data is essential to produce dependable and high-quality data sets that will ultimately be used for analyses. Several excellent reviews detail the stepby-step protocols for metabolomics data processing, including one by The HUSERMET Consortium (Human Serum Metabolome) that outlines procedures for both GC-MS and LC-MS platforms.
17,49 QC samples are necessary for studies with large numbers of samples to provide measures of repeatability within sample batches and to account for potential drift in signal, retention time, or accurate mass before data analysis, as detailed above.
After samples are run, raw data are typically preprocessed using software from instrument companies or from open sources such as XCMS. This process provides alignment of data related to run order and ensures that a metabolite feature is identified with the same parameters in each sample. Data are then corrected based on QC sample signal intensity drift using techniques such as low-order nonlinear locally estimated smoothing function. 17 After this correction, a quality assurance protocol is performed to remove metabolite features with poor repeatability across QC samples. For instance, metabolite features that are detected in <50% of QC samples and those with a relative SD of >30% are removed.
When testing the association of individual metabolites with an outcome of interest, the likelihood of a chance or false association increases with each metabolite considered. For this reason, a traditional statistical approach involves adjusting for multiple comparisons across the number of metabolites studied with Bonferroni or false discovery rate thresholds. This approach is conceptually similar to those for genetic association studies and calculation of genome-wide P values. However, perhaps unlike genetic association studies, many metabolites share biological pathways and are therefore statistically related to each other. To account for this relatedness, multidimensional data reduction approaches have been used to reduce the statistical burden of multiple comparisons. Two commonly used approaches include principal components analysis and hierarchical cluster analysis. Not only do these statistical tools identify correlated metabolites in an unbiased fashion, thus potentially shedding light on previously unappreciated biological relevance, they also reduce the number of analyzed metabolite variables from hundreds or thousands to a few dozen or less.
Another challenge with metabolomics stems from the variability of techniques and data reporting across studies. For instance, detailed methods about sample preparation, instrumentation runs, and QC methods are often lacking in published studies, making independent replication of results difficult. Additionally, metabolite naming is still widely variable, making comparisons of results across studies potentially challenging. Unlike other studies that generate omics data sets, such as genomics, which require a deposit of all raw and processed data into centrally housed and publicly available repositories, metabolomics studies are not currently required to deposit data in a similar fashion. Ideally, such repositories would not only include metabolite abundance and concentration data, but also raw spectral data. In recognition of this need, the National Institutes of Health has created a metabolomics repository for Common Funds projects and a similar repository has been implemented in Europe.
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Metabolite Feature Identification
One of the major challenges with nontargeted metabolomics is the identification of unknown spectral features. In this sense, NMR approaches have a significant advantage over MS-based methods, as multidimensional NMR spectra and isotope specific spectra (ie, 1 H and 13 C-NMR) can provide structural and functional group information for unknown metabolites. Depending on the approach, MS data provides information about retention time, accurate mass, MS and MS/MS spectra, and isotope distributions.
Metabolite features can be classified into one of 3 categories (1) unknown; (2) putative identification; and (3) definitive identification. An unknown feature has no spectral or retention time index match with an authentic standard compound. A putatively identified compound has a match of a single piece of data (eg, high probability score based on spectra, retention time, etc) with a known compound performed under identical experimental conditions. The Metabolomics Standards Initiative defines positive identification as a non-novel metabolite when a minimum of 2 independent and orthogonal approaches relate it to a standard analyzed under the same experimental conditions. 52 Examples of independent orthogonal approaches are retention time/mass spectrum, accurate mass and MS/MS spectra, and 13 C-NMR/2D NMR spectra. A definitive identification still has a chance of false positives because of isobaric species; however cross-platform approaches utilizing NMR and MS can mitigate this concern.
To aid in metabolite identification, spectral and retention time libraries of known analytic standards are required. Whereas it is possible to derive an in-house database of compounds of interest in targeted metabolomics, this is impractical for large-scale nontargeted approaches. For in-depth discussion about metabolite identification using currently available resources, readers are directed to a recent review. 53 As an initiative of the Human Metabolome Project, the HMDB (hmdb. ca) was established as an open access online resource for cataloguing chemical, clinical, and NMR/MS data for any known small molecules found in the human body. The HMDB is composed of ≈110 000 metabolites and allows database querying by chemical structure, molecular weight, or various spectra (eg, MS, MS/MS, GC-MS, 1D or 2D NMR). The HMDB is continually evolving, with the addition of new metabolites and annotations on a frequent basis. Complementary to the HMDB, the Metabolomics WorkBench, part of the National Institutes of Health Common Fund's Metabolomics Program, is a repository for metabolomics data across species and platforms. 54 The MetaboLights database, maintained by the European Bioinformatics Institute, is a similar effort that is underway in Europe. 55 In addition to these databases, resources exist for specific platform applications. For GC-MS single quadrupole and TOF instruments, this includes the NIST library, the Golm Metabolome Database, 56 MetabolomeExpress, 57 METLIN, 58 BinBase, 59 and the FiehnLib. 60 In-house libraries can also be developed from chemical standards as we have done previously in our laboratory. 33, 40, 61 MzCloud (https://www.mzcloud. org) is an open access, searchable database with high-and low-resolution LC-MS/MS data for ≈6700 compounds, including ≈1200 endogenous metabolites and >1800 xenobiotics related to the pharmacological agent or drugs-of-abuse catabolism. The Mass Spectral Feature List Optimizer is another web-based application to aid in peak identification in data generated by LC-MS/MS platforms. 62 Furthermore, the Biological Magnetic Resonance Data Bank 63 has compiled 1 H-NMR, 13 C-NMR, and various 2D NMR spectra for biological metabolites and is easily queried and open access to the scientific community.
In addition to these available resources to aid in peak identification, several other approaches are emerging that leverage the integration of molecular data sets and databases. For instance, the association of variants in genes with known biological function with metabolites from nontargeted metabolomics studies has emerged as a potentially powerful way to identify unknown metabolites. 64 Other groups have demonstrated the power of combining metabolome databases with MS chemoinformatics tools 65 and have used advanced techniques such as in silico generation of mass spectra using quantum chemistry coupled with machine learning methods to aid in peak identification.
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Stable Isotope Applications to Metabolomics
Metabolic pathways are a complex, interconnected network of enzymatically catalyzed reactions. However, the concentrations of most metabolites are maintained within a relatively small dynamic range in vivo, and may not be directly indicative of metabolite flux (metabolic rate) through the associated pathways. Both targeted and nontargeted metabolomics provide a static snapshot of the metabolic status of the biological sample of interest. Metabolic flux provides a dynamic measure of the flow of substrates through metabolic pathways and thus provides a network context for the static, snapshot measurements. When combined, static measurement of metabolite concentrations and metabolic flux provide a comprehensive assessment that can be linked to a wide array of physiological and pathophysiologic phenotypes.
Measurement of metabolic flux often uses stable isotopes (eg, 2 H, 13 C, 15 N), which are nonradioactive and naturally occurring in nature. Stable isotopes have been applied to identify downstream products of a given substrate and to measure flux through metabolic pathways. Stable isotope methods rely on the same instrumentation (NMR and MS) and leverage similar methods as described above for static metabolomics applications. We will briefly discuss the application of 13 C-NMR and MS for stable isotope tracing, commonly referred to as stable isotope-resolved metabolomics, and substrate flux determination, using examples primarily from studies of the isolated perfused heart model. Stable Isotope Enrichment Measurement by 13 C-NMR and MS Both 13 C-NMR and MS can measure the enrichment of metabolites with stable isotopes, but there are nuances between the 2 techniques. With 13 C-NMR, only 13 C-atoms in a metabolite display a chemical shift in resonance. Each 13 C-atom will have a unique resonance shift depending on the chemical microenvironment. Peak splitting of the resonance can occur when a 13 C-atom is covalently adjacent to other 13 C-atoms. This results in additional peaks (doublets, triplets, quadruples) in the spectra, which are collectively referred to as the fine spectra. As 13 C abundance is ≈1.1% in nature, the probability of 2 adjacent 13 C-atoms forming a natural doublet is quite low (≈0.012%). Stable isotope methods take advantage of this fact by assuming that peak splitting in metabolite fine spectra reflects metabolism of a 13 C-substrate. The fine spectra of all 13 C-atoms in a molecule allow for calculation of the fractional enrichment of each carbon atom in the metabolite, as well as defining positional isotopomer(s), that is, a specific isotopic labeling orientation in a given metabolite (review 66 ). In MS, the intensity of ions across a mass/charge (m/z) range is measured. Unlike 13 C-NMR spectra, where each 13 C-atom provides a resonance, a metabolite will provide MS signals based on the molecular weight and charge of the fragment(s) produced during the process of metabolite ionization. A given metabolite may result in one or more ion fragments depending on various parameters, including but not limited to sample derivatization, ionization parameters, and the metabolite's inherent chemical properties. When a metabolite contains one or more stable isotope atoms, the MS spectra displays a shift in the m/z. The envelope of m/z intensities for a given metabolite fragment, including the stable isotope mass shifts, is termed the mass isotopomer distribution. In comparison to positional isotopomers, mass isotopomers are less descriptive and constitute the grouping of positional isotopomers, which have the same number of stable isotopes. Both positional and mass isotopomer data are directly related to the metabolic flux through pathways, with positional isotopomers being more information dense.
For stable isotope experiments, it is important to note that NMR is isotope selective, as NMR methodologies specialize in individual atom isotopes (eg, 15 N, 2 H, 31 P, and 13 C). For unit resolution MS instruments (single or triple quadrupole), a mass shift because of 13 C or 15 N results in the same m/z change; however, for high-resolution accurate mass instruments (eg, TOF and Orbitrap), these differences can be distinguished. The technical limitations associated with the use of NMR and MS for static profiling summarized earlier also apply to stable isotope applications. Overall, despite their differences, 13 C-NMR and MS are complementary methods for metabolomics and stable isotope-based flux experiments.
Stable Isotope-Resolved Metabolomics
While stable isotope tracing/flux experiments (sometimes referred to as stable isotope-resolved metabolomics) are powerful tools to investigate changes in cardiac metabolism in different disease states, they have also been used to better understand metabolism in other organ systems. For instance, early studies using stable isotopes described rates and regulation of hepatic de novo lipogenesis, gluconeogenesis, and glycogen turnover in humans and animals. [67] [68] [69] [70] When combined with the static measures of metabolism obtained by metabolomics, stable isotope tracing studies provide essential insight into potential underlying mechanisms of normal physiology and disease pathogenesis.
In addition to the design principles previously described for metabolomics studies, stable isotope-resolved metabolomics experiments require additional planning considerations. First, an appropriate labeling substrate and its stable isotope enrichment pattern must be selected. Stable isotope tracers that include 13 C, 15 N, and 18 O-atoms are generally accepted to have negligible isotope effects on enzyme activity; however, deuterium ( 2 H) tracers are known to have isotope effects on enzymatic activity. The chosen substrate and labeling strategy must be compatible for studying the pathway of interest. For example, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glucose would be a poor choice to study pyruvate dehydrogenase flux into the tricarboxylic acid (TCA) cycle as the 13 C-atom is lost to 13 CO 2 during the pyruvate dehydrogenase reaction. When using deuterium tracers, another potential challenge lies in the fact that metabolites have labile hydrogens that freely exchange with water (eg, isomerization reactions in glycolysis, keto-enol tautomerization of pyruvate). When using a 2 H-tracer other than deuterated water, this can confound analysis or result in low to negligible enrichment signal.
Another important consideration is the time period of the study and harvesting of the tissue or cell. The simplest metabolic state to probe is one in which the metabolic fluxes are constant over time, that is, metabolic steady state. In this instance, the ideal sampling time is when the isotopic enrichment of metabolites plateau, which is typically assessed through a preliminary time course experiment. However, in in vivo biological systems, the isotopic steady state is not always obtainable. Under these conditions, time course analyses provide kinetic insight into the metabolic pathways of interest. This approach has been used with 13 C-NMR to monitor triacylglyceride dynamics in the isolated perfused heart and can provide tissue-specific metabolite kinetics. 26, 27 Kinetic stable isotope methods are a significant advantage of 13 C-NMR, as these studies can be performed in situ.
Last, when designing an in vivo stable isotope experiment, it is important to consider whether the stable isotope substrate used will produce secondary products that can confound interpretation of the data. 71 Interpretation of enrichment data is simplest when a substrate is used by a single tissue, has a single metabolic fate, and does not produce downstream metabolites that are recycled. If secondary tracer generation is a concern, it is important to monitor those potential metabolites in the plasma and tissues of interest to inform data interpretation.
Substrate Flux Determination in the Isolated Perfused Heart
One of the most common applications for stable isotopes in cardiac metabolism is to interrogate substrate utilization in the isolated perfused heart. As cardiac fuel selection changes during pathophysiologic conditions, it is especially important to have robust methods to measure substrate utilization and entry of anaplerotic substrates into the TCA cycle. A wide variety of 13 C-substrates have been previously used in the perfused heart including glucose, pyruvate, lactate, fatty acids, ketones, and branched-chain amino acids.
The overarching concept for both 13 C-NMR and MS-based techniques is to select a substrate labeling scheme where the 13 C-substrates differentially label acetyl-CoA (Figure 3 ). In the case of 13 C-NMR, tracers that result in different positional isotopomer labeling are desired. For MS, labeling strategies should be designed to result in different mass isotopomers, for example, M+1 versus M+2 acetyl-CoA. With both of these techniques, acetyl-CoA labeling is then measured directly 72 or determined from proxy measurements of acetyl-CoA, for example, glutamate carbons 4 and 5 or labeling of the acetylCoA moiety of citrate (Figure 3) . 22, 73 Using proxy metabolites for acetyl-CoA may seem like an oversimplification, as the TCA cycle spinning results in label scrambling; however, the assumption is that acetyl-CoA-derived carbons in glutamate/ citrate are not influenced by TCA cycle activity, as has been shown to be a reasonable approximation. 74, 75 Mathematical models have been developed that use the enrichment data for acetyl-CoA or its proxy measurements to allow estimation of substrate oxidation and anaplerotic entry rates relative to TCA cycle flux. 72, [76] [77] [78] Further details of 13 C-NMR and MS-based techniques can be found in several reviews. 66, 79 For perfused heart studies, positional isotopomer determination with 13 C-NMR allows for interrogation of >2 substrates at a time; however, only a limited subset of metabolite enrichments can be quantified. On the other hand, MS provides large metabolite coverage of glycolytic, TCA cycle, and other pathways. As a result, MS methods can provide insight into pyruvate/lactate metabolism, and the data-rich nature of MS allows a comprehensive analysis of enrichment data with more rigorous flux methods, such as 13 C-metabolic flux analysis.
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Applications in Cardiovascular Diseases
With the growing appreciation of the metabolic basis of cardiovascular disease, metabolomics has become a powerful investigative tool. One important application of metabolomics is the discovery of novel biomarkers of cardiovascular disease. Indeed, the American Heart Association recently released a statement summarizing the clinical applications of metabolomics in cardiovascular disease. 48 In addition, with the ability to measure changes in circulating and tissue concentrations of metabolites, metabolomics can provide an integrated view of whole body metabolic disturbances in different disease states, thus providing key insights into cardiovascular disease pathophysiology. Moreover, by coupling metabolomics with stable isotope and metabolic flux approaches, and by integrating metabolomics data with other omics data sets, the functional consequences, and molecular underpinnings of cardiovascular disease-related metabolic disturbances can be elucidated. Below, we highlight applications of metabolomics technologies to several common cardiovascular diseases, with an emphasis on recent advances in the field (Table 4) . Given a recent review on human/clinical applications of metabolomics in cardiovascular disease, 48 we focus here on findings from studies using model organisms that provide insight into cardiovascular disease pathogenesis.
Cardiac Hypertrophy
As the heart undergoes hypertrophy, it must alter its metabolism to support growth. Metabolomics studies have revealed that this process varies considerably depending on the physiological conditions. For instance, the heart hypertrophies in response to chronic exercise training (physiological hypertrophy) as well as chronic hemodynamic stresses (pathological hypertrophy). Although the cardiac structure is grossly similar in these 2 conditions, the hearts have distinct molecular and metabolic profiles that inform the underlying growth programs. Application of metabolomics, isotope tracing, and metabolic flux methods have illuminated the molecular and metabolic changes that characterize these 2 forms of hypertrophy.
Studies using both radioactive and stably labeled carbon substrates in isolated perfused hearts first demonstrated accelerated glycolysis in pathological cardiac hypertrophy, which has since become a hallmark of metabolic remodeling in this condition. 24, [99] [100] [101] [102] This increase in glycolysis is accompanied by an uncoupling from glucose oxidation and lower rates of long-chain fatty acid oxidation, 103, 104 whereas rates of mediumchain fatty acid oxidation, a process that does not require carnitine for transport into the mitochondria, are not reduced. 105 In contrast with pathological cardiac hypertrophy, long-chain fatty acid oxidation, and glucose oxidation rates are increased in physiologically hypertrophied hearts, whereas glycolytic rates are reduced. 106 These concepts have recently been further elaborated in comprehensive in vivo experiments. An 8-week nocturnal wheel running-based exercise training program in C57BL/6J mice resulted in a 10% increase in biventricular weight compared with nonexercising controls. Minimal differences were seen in the gene expression profiles, as measured by gene array, in hearts from the exercised and control animals. However, there were significant changes in the metabolite profiles, as measured by targeted quantitative LC-MS/MS, including decreased medium-and long-chain acylcarnitines, succinate, and lactate, suggesting increased carbon flux through oxidative metabolic pathways. 81 Given the lack of gene expression changes, the differences in metabolites likely reflect differences in posttranslational modification or allosteric regulation of key metabolic enzymes. In the same study, pathological cardiac hypertrophy was achieved using transverse aortic constriction (TAC) in mice as a model of pressure overload. After 4 weeks, these animals developed significant biventricular hypertrophy compared with sham-operated controls but maintained left ventricular function. In contrast to physiological hypertrophy, hearts from the TAC mice underwent gene reprogramming, with upregulation of genes involved in the hypertrophic growth response and inflammation, and downregulation of fatty acid transport and oxidation genes. These gene expression changes were similar to those seen in failing hearts. Interestingly, there were very few differences in the metabolite profiles between the pathological hypertrophy and control hearts. Taken together, despite similar changes in cardiac hypertrophy, these results demonstrate distinct regulation of metabolic responses in the heart in response to physiological versus pathological stress, involving primarily altered posttranscriptional regulation of metabolic enzymes and altered static metabolomics profiles in the former, and changes in transcriptional control of metabolic enzymes and little change in static metabolic profile in the latter.
Another study similarly used gene expression profiling and metabolomics to characterize the metabolic changes that occur during the transition from cardiac hypertrophy to failure in the Dahl salt-sensitive rat. 107 Although rats fed a high-salt diet showed an increase in cardiac glucose uptake compared with controls, there were no significant changes in expression of glycolytic, fatty acid oxidation, TCA cycle, nucleotide metabolism, or amino acid metabolic genes. After the transition to heart failure (HF), however, there was a significant downregulation of fatty acid oxidation genes and transcriptional regulators of fatty acid oxidation and mitochondrial function such as PPARα (peroxisome proliferatoractivated receptor alpha) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha. Moreover, metabolomics showed that failing hearts had a decrease in TCA cycle intermediates and activation of the glycolysis-related pentose phosphate pathway, which regulates the cellular redox state by maintaining reduced glutathione levels. Although earlier studies also showed an upregulation of the pentose phosphate pathway in pathological cardiac hypertrophy, 108, 109 others have failed to demonstrate a change in flux through pentose phosphate pathway-related enzymes in hypertrophied hearts, 110, 111 so the precise role of this pathway, which provides an alternative fate for glycolytic intermediates, remains unknown. 25 
Heart Failure
Under normal fasting conditions, the healthy heart generates 60% to 90% of its energy through the mitochondrial oxidation of fatty acids, with the remainder supplied by oxidation of glucose, lactate, and ketones. 112 As discussed above, pathological structural remodeling such as cardiac hypertrophy results in well-described reprogramming of cardiac metabolic pathways, leading to an overall increased reliance on glucose metabolism (increased glucose uptake and glycolysis) with a decrease in fatty acid oxidation. At the transcriptional level, changes in metabolic gene expression in the hypertrophied heart resemble a reversal of metabolic maturation that occurs in the transition from a fetal to adult heart. Thus, many have described the metabolic changes that occur in cardiac hypertrophy, and ultimately HF, as a reversion to a fetal metabolic program. Importantly, these metabolic changes often precede cardiac structural changes in the failing heart suggesting that metabolic reprogramming represents an early event in HF pathogenesis. 2 Although a shift from fatty acid oxidation to glucose utilization may facilitate cardiac hypertrophy and allow early adaptation of the heart to hemodynamic stresses, 113 prolonged reliance on glucose likely results in an ultimate state of ATP depletion and bioenergetic starvation as cardiac hypertrophy advances to overt HF. 99, 114 Additionally, during the transition from cardiac hypertrophy to failure, mitochondrial number, and function progressively decline, leading to an overall decrease in the oxidative metabolism of most fuels and a propagation of energy deficit. 115 These concepts were demonstrated in a study that performed gene and protein Mouse, TAC (heart failure); human (heart failure) 83 ; Mouse, MI (heart failure) 84 
LC-MS/MS; GC-MS
Heart, plasma Accumulation of BCAA and BCKA in heart tissue and plasma in HF; delayed HF progression with increased heart BCAA metabolism LC-MS/MS Plasma TMAO levels associated with future CVD events BCAA indicates branched-chain amino acids; BCKA, branched-chain α-ketoacids; CAD, coronary artery disease; CVD, cardiovascular disease; GC-MS, gas chromatography-mass spectrometry; HF, heart failure; LC-MS/MS, liquid chromatography-mass spectrometry/mass spectrometry; LVAD, left ventricular assist device; MI, myocardial infarction; NMR, nuclear magnetic resonance; SCDA, short-chain dicarboxylacylcarnitine; TAC, transverse aortic constriction; TCA, tricarboxylic acid; and TMAO, trimethylamine N-oxide.
expression coupled with metabolomics in tissue from patients with end-stage HF undergoing left ventricular assist device placement. Compared with heart tissue from individuals without HF, the failing hearts showed evidence of overall decreases in substrate oxidation and mitochondrial function. These molecular changes were partially reversed after a median of 55 days of ventricular off-loading with left ventricular assist device support. 80 Over the past several decades, research into the metabolic changes that occur during HF has primarily focused on changes in fatty acid and glucose metabolism as discussed. Given that these 2 substrates provide the majority of energy to the heart in healthy and failing conditions, this focus has been appropriate. However, this hypothesis-driven approach has tended to neglect other metabolic pathways in the failing heart. Unbiased molecular profiling affords a more global perspective on changes that occur in HF and permits the discovery of previously unappreciated biological pathways that contribute to disease pathogenesis. As such, metabolomics has recently helped to elucidate new underlying pathophysiological mechanisms and adaptations of HF.
Using a systems biology approach, unbiased transcriptomic profiling and targeted quantitative metabolic profiling were used to explore the molecular changes underlying pathological cardiac hypertrophy, achieved via TAC, and HF, achieved via TAC plus myocardial infarction in mice. 81 Although both the hypertrophic and failing hearts underwent significant gene reprogramming of many metabolic pathways involved in oxidative phosphorylation, very few differences in the metabolite profiles were observed between the hypertrophic and control hearts. However, hearts from animals with frank HF had an accumulation of medium-and long-chain acylcarnitines and lactate and a decrease in most TCA cycle intermediates, suggesting impaired oxidative metabolism. Thus, although pathological hypertrophy and HF shared transcriptional changes in metabolic genes, metabolomics revealed that the functional results of these changes were not apparent until HF developed. The mechanisms leading to this metabolic transition from cardiac hypertrophy to failure are unclear; however, this study highlights the power of combining omics platforms to uncover metabolic bases of cardiac disease.
Another study used a combination of LC-MS/MS and GC-MS techniques to provide an unbiased assessment of metabolic changes in TAC-and infarction-related HF in mice. 82 They found that both conditions resulted in significant changes in up to 40% of the 288 measured metabolites. There were timedependent decreases in several metabolites such as purines, acylcarnitines, fatty acids, and sphingolipids suggesting global effects in energy metabolism, with concomitant increases in markers of oxidative stress. Additionally, they observed an accumulation of branched-chain amino acids (BCAA) in the failing hearts which was associated with myocardial insulin resistance.
Following this study, several additional investigations have used integrated metabolomics approaches to address the contribution of cardiac BCAA metabolism in HF. For example, transcriptomics and LC-MS/MS and GC-MS based metabolomics were applied to a model of TAC-induced HF in mice to reveal a coordinated downregulation of the BCAA catabolic pathway in failing hearts, with an associated accumulation of tissue and circulating BCAA and branchedchain α-ketoacids. 83 Similar transcriptional and metabolite changes were seen in human heart tissue and plasma from human HF patients. Pharmacological treatment to enhance cardiac BCAA catabolism resulted in delayed HF progression in TAC-treated mice suggesting that downregulation of the cardiac BCAA pathway may contribute to HF pathogenesis. Similar findings have since been demonstrated in MI-induced HF mouse models. 84 In addition to the emerging role of BCAA in HF metabolism, 2 studies have recently used metabolomics and other omics strategies to demonstrate a role of ketone metabolism in HF. A proteomics approach in mouse models of pathological hypertrophy (TAC) and HF (TAC plus MI) showed that in addition to the expected downregulation of proteins involved in fatty acid oxidation, there was a concurrent upregulation of key enzymes involved in ketone oxidation. 85 These changes in protein expression were accompanied by increased oxidation of 13 C-labeled ketone bodies in an isolated perfused heart system as measured by NMR as well as tissue accumulation of downstream metabolites of ketone oxidation as measured by targeted quantitative LC-MS/MS-based metabolomics. In a separate study of human HF, unbiased lipidomic profiling and targeted quantitative metabolomics were applied to the myocardium of end-stage human HF patients. 86 This study likewise showed evidence of impaired fatty acid oxidation in failing myocardium with an increase in downstream metabolites of ketone oxidation and a concurrent upregulation of key enzymes in the ketone oxidation pathway. Whether the increased reliance on ketones for energy in the failing heart is an adaptive or maladaptive process is still unclear. 116 Because of the inherent difficulty in obtaining myocardial tissue samples, human metabolomics studies of HF have generally analyzed metabolites in serum or plasma (reviewed 117 ). Thus, the results reflect integrated systemic metabolism in HF, not cardiac metabolism per se. Because HF triggers widespread changes in systemic metabolism, changes in circulating metabolites in HF often reflect metabolic changes in peripheral tissues in addition to those that occur in the heart. 117 Indeed, HF-induced alterations in peripheral metabolism are now considered integral to HF pathogenesis and disease progression. 118 Several metabolomics studies have revealed the importance of circulating long-chain acylcarnitines as a metabolite signature in HF. For instance, using targeted LC-MS/MS quantitative metabolomics, long-chain acylcarnitines were significantly associated with cardiovascular outcomes in the HF-ACTION clinical trial (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) of individuals with HF with reduced ejection fraction (HFrEF). 87 Moreover, these acylcarnitine species were also significantly increased in the circulation of individuals with end-stage HFrEF and decreased after ventricular off-loading with left ventricular assist device implantation. 87 Plasma long-chain acylcarnitines have also been shown to increase according to HFrEF clinical severity. 119, 120 Although mechanistic studies are needed to determine the cause of these circulating acylcarnitine species, these findings are thought to reflect possible perturbations in systemic fatty acid oxidation and mitochondrial dysfunction.
Lipidomics, a subfield of metabolomics that measures lipid molecular species, has also provided insight into biomarkers and disease pathogenesis in metabolic disorders and cardiovascular diseases. 122 For example, lipidomics has revealed that cardiolipin, an important lipid component of the inner mitochondrial membrane that contributes to the function of many mitochondrial proteins, is actively remodeled during the progression of heart diseases such as HF. 123, 124 Cardiolipin seems to be critical in diabetes mellitus-related cardiac dysfunction as well. Lipidomics performed in diabetic mouse hearts showed depletion of cardiolipin and its precursors as well as the enzymes in the cardiolipin metabolic pathway, which may lead to the mitochondrial dysfunction seen in diabetic myocardium. 125 Furthermore, genetic deletion of the enzyme that contributes to cardiolipin remodeling prevented diet-induced obesity and improved hepatic mitochondrial function and lipid oxidation in mice. 126 Although all of the HF studies discussed above, either animal or human, were performed in HFrEF, HF with preserved ejection fraction (HFpEF) currently represents up to 50% of HF cases in the United States. 127 In many ways, despite sharing clinical HF characteristics, HFpEF and HFrEF are thought to represent distinct clinical entities. Interestingly, in a study of individuals with HFrEF, HFpEF, and normal controls, circulating long-chain acylcarnitines, as measured by targeted LC-MS/MS quantitative metabolomics, differed significantly across groups, with increasing concentrations seen from control to HFpEF to HFrEF. 88 Thus, HFrEF and HFpEF seem to share common metabolic derangements, independent of ejection fraction, but the data set also provides evidence of progression of metabolic abnormalities with disease severity.
Myocardial Ischemia and Infarction
Sudden decreases in oxygen and nutrient supply as seen in myocardial ischemia and infarction lead to well-described changes in cardiac metabolism, in particular in fatty acid and glucose oxidation (reviewed [128] [129] [130] ). Moreover, the sudden reintroduction of oxygen and nutrients during reperfusion leads to the generation of mitochondrial reactive oxygen species that can lead to oxidative damage and ultimately cellular death. Once thought to be a nonspecific response to the restoration of oxygen to ischemic tissues, metabolomics has recently revealed that mitochondrial reactive oxygen species production during reperfusion is regulated through tissue succinate levels. 89 Using comparative in vivo metabolomics in mouse models of ischemia-reperfusion injury (in brain, kidney, heart, and liver) and 13 C-substrate tracing in isolated ischemia-reperfusion hearts, it was found that succinate accumulates in every ischemic tissue, and that oxidation of succinate during reperfusion drives mitochondrial reactive oxygen species accumulation and injury. Thus, modulation of succinate metabolism during reperfusion may offer a viable approach to reduce ischemia-reperfusion injury.
Metabolomics has also recently been used to explore the role of cardiac BCAA metabolism in myocardial energetics and ischemia-reperfusion injury. A genetic mouse model of impaired whole body BCAA catabolism (knockout of the PPM1K [protein phosphatase Mg 2+ /Mn 2+ -dependent 1K] enzyme) showed a ≈50% decrease in glucose oxidation and a reciprocal increase in fatty acid oxidation as measured by 13 C-NMR isotopomer analysis of isolated perfused hearts. These changes in fuel selection were related to decreased glucose uptake in the heart as well as a proposed BCAA-mediated inhibition of pyruvate dehydrogenase, which controls the flux of pyruvate into the mitochondria and thus regulates glucose oxidation. Moreover, hearts from the knockout animals had exacerbated ischemia-reperfusion injury when compared with controls, which was mitigated by either enhanced BCAA catabolism or enhanced glucose oxidation. 90 Although these findings suggest a direct interplay of BCAA and glucose metabolism, further investigations are required to fully understand the putative mechanisms involved.
In addition to providing new insights into the metabolic control of ischemia and reperfusion injury in animal models of disease, metabolomics has also been used to describe the metabolic changes that occur during myocardial ischemia and infarction in human subjects. LC-MS/MS-based metabolomics was performed on plasma from 36 individuals before and after exercise stress testing, 18 of whom demonstrated inducible ischemia and 18 of whom did not. Pathway analysis of the 173 measured metabolites revealed significant changes of 6 citric acid cycle related metabolites in individuals with inducible ischemia. The investigators then developed a metabolic ischemia risk score using these 6 metabolites and showed in training and validation cohorts that they could reliably discriminate individuals with inducible ischemia. 91 The same group also sought to identify new metabolite markers of myocardial injury in 36 individuals undergoing planned myocardial infarction, via alcohol septal ablation, as a treatment for hypertrophic obstructive cardiomyopathy. Frequent serial blood samples were obtained from both the periphery as well as the coronary sinus during the procedure. Patients undergoing diagnostic cardiac catheterization and those with spontaneous myocardial infarction were used as negative and positive controls, respectively. Targeted LC-MS/MS-based metabolomics was performed on the plasma. Changes in several metabolites, including certain amino acids, products of pyrimidine metabolism and the pentose phosphate pathway, were observed in as early as 10 minutes postplanned infarction in both coronary sinus and peripheral blood. These metabolites were subsequently used to differentiate with high accuracy individuals undergoing coronary angiography for spontaneous myocardial infarction from those undergoing diagnostic coronary angiography.
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Cardiometabolic Diseases
Perhaps not surprisingly, over the past decade metabolomics has significantly advanced the understanding of several metabolic disorders. 131 One of the most consistent observations has been the association of BCAA and related metabolites (including BCAA catabolic intermediates and the aromatic amino acids phenylalanine and tyrosine) with insulin resistance and type 2 diabetes mellitus. Although an association of circulating BCAA and obesity and insulin secretion was initially described in the 1960s, 132 metabolomics has provided a much broader insight into these associations. For instance, using a targeted MS/MS approach, a BCAA metabolite factor was better able to discriminate lean and obese individuals and was more strongly correlated with markers of insulin resistance than lipid-related metabolites, which were previously thought to drive obesity-related perturbations in glucose homeostasis. 47 Moreover, supplementation of a high-fat diet with BCAA promoted insulin resistance in rats, independent of weight gain, suggesting a causal effect of BCAA in mediating this process, 47 whereas BCAA restriction in a genetic rat model of obesity improved insulin sensitivity. 133 Because of this observation, several additional studies using different metabolomics platforms in different human cohorts, have not only confirmed the association of BCAA with insulin resistance, [134] [135] [136] [137] but have also shown that BCAA predicts the development of diabetes mellitus 138 and predict improvement in insulin sensitivity with weight loss. 139, 140 The mechanisms underlying the association of BCAA with obesity-related metabolic disorders remain unclear. However, ongoing basic science investigations are beginning to unveil the complex interplay between BCAA, glucose and lipid metabolism that may contribute to systemic metabolic disturbances.
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Cardiovascular Risk Prediction
Many of the metabolomics applications discussed above illustrate the utility of the technology to unveil underlying metabolic mechanisms of cardiovascular diseases. An equally important role for metabolomics is in the identification of biomarkers for prediction of cardiovascular disease risk. 48, 142, 143 For instance, targeted quantitative LC-MS/MS-based metabolomics has been used to demonstrate the independent predictive value of a circulating BCAA metabolite factor for obstructive coronary artery disease in individuals undergoing diagnostic coronary angiography. 93, 94 In this same cohort, baseline levels of a metabolite factor containing short-chain dicarboxylacylcarnitine species (SCDA) strongly predicted death/myocardial infarction in multivariable regression models. 93 In individuals undergoing coronary artery bypass grafting, the SCDA metabolite factor was also shown to predict a composite outcome of myocardial infarction, need for percutaneous intervention, repeat coronary artery bypass grafting and death in multivariable regression models. 144 Moreover, this metabolite factor significantly improved mortality risk reclassification and discrimination when added to clinical models that contained standard risk factors. 95 One very rapidly developing area of blood-based metabolomics in cardiovascular risk prediction is the role of the gut microbiome in determining circulating host metabolite levels. A recent study has demonstrated an association of gut microbiota composition with circulating BCAA concentrations. 40 Another example is the metabolite trimethylamine N-oxide (TMAO). In a seminal study, unbiased LC-MS/MS metabolomics was applied in human cohorts at high-risk for cardiovascular disease to identify new markers of future cardiovascular events. Three metabolites of the dietary lipid phosphatidylcholine (found in red meat)-choline, TMAO, and betaine-independently predicted cardiovascular risk in a training and validation cohort. A subsequent study demonstrated that feeding mice a diet supplemented with choline or TMAO promoted atherosclerosis; however, this effect was lost when using germ-free mice. Additionally, suppression of the intestinal microflora protected atherosclerosis-prone mice from dietary-choline-induced atherosclerosis, confirming the role of the gut microbiota in mediating the effect of TMAO in circulation. 145 Further studies in humans have confirmed the link between dietary choline intake, gut microbiota, and circulating TMAO levels. 98 Additionally, studies have validated the original findings of elevated TMAO and increased cardiovascular and mortality risk in a wide range of populations including individuals undergoing coronary angiography and those with the stable coronary disease, acute coronary syndrome, HF, chronic kidney disease, peripheral arterial disease, and diabetes mellitus. 98, [146] [147] [148] [149] [150] [151] Importantly, preclinical studies using a compound that inhibits trimethylamine production in the gut reduced circulating TMAO levels in atherosclerosis-prone mice fed a high-choline diet while inhibiting atherosclerotic lesion development suggesting potential therapeutic options for humans in the future.
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Future Directions
The integration of molecular data sets represents a powerful and emerging approach for obtaining a more comprehensive view of the complex underpinnings of cardiovascular and cardiometabolic disorders. Over the past decade, several groups have integrated GWAS (Genome-Wide Association Study) and metabolomics data to describe the contribution of genetic variation to circulating metabolite concentrations. 143, [153] [154] [155] [156] [157] [158] Similar studies have also recently been performed with epigenetics and metabolomics. 159 Such metabolic quantitative trait loci studies can be used for focused hypothesis testing. As an example, metabolic quantitative trait loci studies helped to demonstrate that 2 flavin monooxygenase family members oxidize trimethylamine to TMAO and that variants in the FMO3 gene directly affect circulating TMAO levels and increase susceptibility to atherosclerosis in mice. 160 Metabolic quantitative trait loci analyses may also provide insight into functional annotation of genetic variants. For instance, integration of variants in the TCF7L2 gene, which have previously been identified as a risk locus for type 2 diabetes mellitus, with plasma metabolomics revealed alterations in phospholipid metabolism in response to glucose tolerance testing in individuals with the risk allele, suggesting that these metabolic changes may be early pathogenic events before development of diabetes mellitus. Metabolic quantitative trait loci analyses may also be a powerful approach for hypothesis generation. Integration of metabolomics, transcriptomics, and genetics in liver samples from an F2 intercross between diabetes mellitus-resistant and diabetes mellitus-susceptible mouse strains revealed certain genomic regions that were responsible for metabolic and transcriptional variation. Advanced computational analysis of the data set showed a causal network that linked variation in glutamate levels to regulation of a key gluconeogenic enzyme. This potential regulatory network was then experimentally tested in cellular studies to show that glutamate-induced expression of the gluconeogenic gene network. 161 In addition to demonstrating the genetic bases of metabolic variation among individuals, such integrative systems biology approaches help to identify previously unappreciated links between biological pathways. As an example, to gain insight into the molecular underpinnings of the SCDA metabolite cluster discussed above, metabolomics data were integrated with genetics, epigenetics and transcriptomics in 3512 individuals. Genome-wide analysis revealed association of SCDA levels with variants in genes that regulate components of endoplasmic reticulum stress. Importantly, these particular variants also independently predicted cardiovascular events. Additionally, association of genome-wide methylation profiles with SCDA levels identified 2 endoplasmic reticulum stress genes that were differentially methylated. Expression quantitative trait loci analysis of the genetic variants linked to SCDA via GWAS likewise identified endoplasmic reticulum stress pathways, specifically those reporting on the ubiquitin-proteasome pathway. 96 Thus, through the integration of multiple molecular data sets, the pathophysiological origins of this novel metabolic biomarker have started to emerge.
Given the shared technology of MS, and the fact that many metabolites such as acetyl-CoA participate in posttranslational modification, the integration of metabolomics and proteomics has also emerged as a way to understand the metabolic regulation of important cellular processes in relation to cardiovascular disease pathology. 162 For instance, comparison of the proteome and metabolome of PKC (protein kinase C)δ +/+ and PKCδ −/− hearts revealed an important role of PKCδ in the regulation of cardiac glucose metabolism during ischemic preconditioning, 163, 164 and other studies suggest similar roles for additional PKC isoforms. 165 Integrated proteomic and metabolomics studies have also expanded the metabolic understanding of atherosclerosis in apoE −/− mice. 166 Multiple barriers exist to integrated omics analyses, especially in the setting of utilizing publicly available data sets where critical information such as methods of sample preparation, methods of instrument operation, and QC methods are lacking. Moreover, locating data in the first place may be challenging. Efforts are underway to address these concerns and needs. One example is OmicsDI (www.omicsdi.org), an open-source platform that can be used to access, discover, and disseminate omics data sets. 167 This platform stores biological and technical metadata from multiple repositories and indexes the information according to a molecular entity (eg, gene, transcript, protein, metabolite), data source (tissue, species), and disease state. With such resources becoming more widely available, users can access multiomics data sets for data-driven experiments and new interpretive insights.
The ultimate goal of integrated omics analysis in the field of metabolism is to develop genome-scale metabolic models for disease states of interest. This systems biology approach takes into account molecular variation (genomics, transcriptomics, proteomics) along with flux through metabolic pathways to provide maps of metabolic networks in physiological systems, such as specific tissues, organs, or even whole organisms. 168 Early efforts to create genome-scale metabolic network reconstructions showed their power to provide insight into responses of metabolism to changes in intracellular and extracellular conditions. 169 In regards to cardiovascular disease, the CardioNet study used systems biology to reconstruct the metabolic network of the human cardiomyocyte and then used flux-balance analysis to show the ability of the network to respond to differing conditions of fuel supply. 170 This network has subsequently been used to model flux rates of substrate metabolism in working hearts under varying conditions. 171 Integrated omics analyses have the potential to unveil mechanisms underlying the molecular remodeling in disease states. Emerging approaches using in vivo metabolic flux techniques offer an additional powerful tool to investigate the functional consequences of these differences. For example, a hyperpolarized 13 C-NMR-based approach has been used to assess simultaneous metabolic flux changes across organs in the diabetic rat. Diabetes mellitus reduced pyruvate dehydrogenase flux by 80% and 40% in the heart and liver, respectively, whereas the incorporation of 13 C to alanine was reduced by 55% in liver but not changed in heart. 28 Such approaches to measure in vivo tissue flux of substrates in different cardiovascular disease states will expand the ability to translate the static findings of metabolomics into dynamic models to test metabolic-based hypotheses of disease.
Although integrated omics approaches offer an exciting and powerful view of the molecular bases of disease, they also present major computational challenges. The statistical and analytic capabilities for handling and integrating diverse molecular data sets have lagged behind the technology to generate the data. Therefore, further advances in the field will first require more sophisticated statistical approaches to fully capitalize on the promise offered by integrated systems biology.
172
Conclusions
The postgenomic era provides opportunities to gain insight into cardiovascular disease risk and pathogenesis. Because most cardiovascular diseases share disturbances in cardiac metabolism, metabolomics, in particular, has advanced the understanding of the molecular underpinnings of these conditions. Unlike other omics technologies, metabolomics provides a functional integration of upstream genetic, transcriptomic, and proteomic variation, as well as environmental exposures, thus reflecting molecular processes more proximal to disease states. Newer technologies are expanding our ability to describe the metabolome and quantify flux through metabolic pathways to trace the fates of metabolic substrates. In parallel, development of sophisticated computational approaches must continue to allow the integration of multiple omics data sets to provide a more comprehensive view of the molecular foundation of cardiovascular diseases. As the understanding of the metabolic basis of cardiovascular diseases continues to grow, metabolomics will remain at the forefront of scientific discovery in this arena.
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